Search Results - ACTIV-2/A5401 Study Team

  • Showing 1 - 6 results of 6
Refine Results
  1. 1

    Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibod... by Urvi Parikh, Amy Heaps, Daniela Moisi, Kelley Gordon, John Mellors, Manish Choudhary, Rinki Deo, Carlee Moser, Paul Klekotka, Alan Landay, Judith Currier, Joseph Eron, Kara Chew, Davey Smith, Jonathan Li, Scott Sieg, ACTIV-2/A5401 Study Team

    Published in Pathogens and Immunity (2024-08-01)
    Get full text
    Article


  2. 2

    Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non... by Katya Corado, Kara Chew, Mark Giganti, Ying Mu, Courtney Fletcher, Judith Currier, Eric Daar, David Wohl, Jonathan Li, Carlee Moser, Justin Ritz, Arzhang Javan, Gene Neytman, Marina Caskey, Michael Hughes, Davey Smith, Joseph Eron, ACTIV-2/A5401 Study Team

    Published in Pathogens and Immunity (2024-05-01)
    Get full text
    Article


  3. 3

    Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. by Tin Phan, Carolin Zitzmann, Kara W Chew, Davey M Smith, Eric S Daar, David A Wohl, Joseph J Eron, Judith S Currier, Michael D Hughes, Manish C Choudhary, Rinki Deo, Jonathan Z Li, Ruy M Ribeiro, Ruian Ke, Alan S Perelson, ACTIV-2/A5401 Study Team

    Published in PLoS Pathogens (2024-04-01)
    Get full text
    Article


  4. 4

    Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses by Sydney I. Ramirez, Alba Grifoni, Daniela Weiskopf, Urvi M. Parikh, Amy Heaps, Farhoud Faraji, Scott F. Sieg, Justin Ritz, Carlee Moser, Joseph J. Eron, Judith S. Currier, Paul Klekotka, Alessandro Sette, David A. Wohl, Eric S. Daar, Michael D. Hughes, Kara W. Chew, Davey M. Smith, Shane Crotty, for the Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team

    Published in JCI Insight (2022-12-01)
    Get full text
    Article


  5. 5

    Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2 by Sydney I. Ramirez, Paul G. Lopez, Farhoud Faraji, Urvi M. Parikh, Amy Heaps, Justin Ritz, Carlee Moser, Joseph J. Eron, David Wohl, Judith Currier, Eric S. Daar, Alex Greninger, Paul Klekotka, Alba Grifoni, Daniela Weiskopf, Alessandro Sette, Bjoern Peters, Michael D. Hughes, Kara W. Chew, Davey M. Smith, Shane Crotty, for the Accelerating COVID-19 Therapeutic Interventions and Vaccines-2 (ACTIV-2)/A5401 Study Team

    Published in JCI Insight (2024-12-01)
    Get full text
    Article


  6. 6

    Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 by Kara W. Chew, Carlee Moser, Eric S. Daar, David A. Wohl, Jonathan Z. Li, Robert W. Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia Li, Manish C. Choudhary, Rinki Deo, Carlos Malvestutto, Paul Klekotka, Karen Price, Ajay Nirula, William Fischer, Veenu Bala, Ruy M. Ribeiro, Alan S. Perelson, Courtney V. Fletcher, Joseph J. Eron, Judith S. Currier, ACTIV-2/A5401 Study Team, Michael D. Hughes, Davey M. Smith

    Published in Nature Communications (2022-08-01)
    Get full text
    Article


Search Tools: